aceTRV-2026-1229Version 1 · Certified
Reason for this version
Certified into the record
Canonical text (the exact bytes fingerprinted)
TRUVACE RECORD VERSION record: TRV-2026-1229 version: 1 kind: certified reason: Certified into the record timestamp: 2026-10-01T06:54:31.424131Z status: published lens: g_space sector: health headline: Profluent And BioMarin Pharmaceutical Inc. Partner To Design Novel Medicines Using AI dek: Profluent announced a collaboration with BioMarin Pharmaceutical Inc. to design and optimize novel enzyme therapies for BioMarin's pipeline. Under the agreement, Profluent will apply its foundational... gain_title: Profluent will use its AI platform to design and optimize novel enzyme therapies for BioMarin's drug pipeline under a new collaboration. problem_title: (none) trace_subject: (none) gain_reading: Profluent will use its AI platform to design and optimize novel enzyme therapies for BioMarin's drug pipeline under a new collaboration. gain_evidence: design and optimize novel enzyme therapies for BioMarin's pipeline | Profluent announced a collaboration with BioMarin Pharmaceutical Inc. problem_reading: (none) problem_evidence: (none) quick_read: Profluent announced a collaboration with BioMarin Pharmaceutical Inc. to design and optimize novel enzyme therapies for BioMarin's pipeline, with Profluent applying its foundational technology under the agreement. The partnership illustrates use of AI-driven protein design in pharmaceutical development, but the supplied text does not detail specific targets, timelines, performance results, or clinical outcomes, leaving efficacy and translational impact uncertain. limitation: tag: Evidence-backed gain key_points: Profluent announced a collaboration with BioMarin Pharmaceutical Inc. | The stated goal is to design and optimize novel enzyme therapies for BioMarin's pipeline. | Under the agreement Profluent will apply its foundational AI technology to the effort. rundown: On September 30, 2026, Profluent announced a collaboration with BioMarin Pharmaceutical Inc. focused on novel enzyme therapies. The agreement positions Profluent to apply its foundational platform to design and optimization work intended to support BioMarin's pipeline. sources: - journalism | MarketScreener | https://www.marketscreener.com/news/profluent-and-biomarin-pharmaceutical-inc-partner-to-design-novel-medicines-using-ai-ce785ad3d88bf623 | 2026-09-30 prev: 0000000000000000000000000000000000000000000000000000000000000000
- sha256
- 8507a350b89fd66b3a9cca5d7d2fc9cf31c7704f64c688898ed83b06a23bf708
- previous
- 0000000000000000000000000000000000000000000000000000000000000000
Verify this record
How to verify without trusting this page
Fetch the canonical text of any version from /api/record/TRV-2026-1229 and hash it yourself — for example shasum -a 256 on the saved canonical field. The result must equal content_hash, and each version’s text ends with prev:followed by the prior version’s hash (version 1 chains to 64 zeros). If a single character of any version had been altered since certification, the chain would not reproduce.